Strona główna・Stock List・Cerus Corp

Cerus Corp

Closed

SectorHealthcare

2.34 1.3

Buy Sell

Overview

Share price change

24h

Current

Min

2.2

Max

2.35

Key metrics
By Trading Economics
Income	-1.3M -3M
Sales	-2.5M 57M
EPS	-0.01
Profit margin	-5.191
Employees	261
EBITDA	-1.5M -712K

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+120.26% upside

Dividends
By Acuity
Next Earnings	5 lis 2026

Market Stats
By TradingEconomics
Market Cap	-182M 433M
Previous open	1.04
Previous close	2.34

News Sentiment

By Acuity

50%

156 / 340 Ranking in Healthcare

Cerus Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 sie 2026, 19:43 UTC

Cerus Corp shares are higher Wednesday, recovering from an earlier decline amid high trading volume. Broader market sentiment is influenced by ADP's employment report.

4 sie 2026, 19:11 UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

3 sie 2026, 19:56 UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

31 lip 2026, 23:06 UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

30 lip 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

29 lip 2026, 19:56 UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

28 lip 2026, 16:02 UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

27 lip 2026, 20:07 UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

24 lip 2026, 19:06 UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

23 lip 2026, 09:01 UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

22 lip 2026, 15:46 UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

21 lip 2026, 21:41 UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Peer Comparison

Price change

Cerus Corp Forecast

Price Target

By TipRanks

120.26% upside

12 Months Forecast

Average 5 USD 120.26%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forCerus Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Cerus Corp - Dist in the past 3 months.

Sentiment

By Acuity

156 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.